EULAR Abstract Archive OP0283 (2024) LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL 3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

EULAR Abstract Archive RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX) 870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

EULAR Abstract Archive OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024

• EULAR Abstract Archive

Zoe @ZoeClarkOsteo from @NASSexercise @NASSchiefexec presenting her work from the Your SpAce self-management programme which covers topics on pain, fatigue, flares and much more #EULAR2024 @RheumNow https://t.co/q81JDHu7Oj

• https://twitter.com/synovialjoints/status/1801931105437634880/photo/1
• https://twitter.com/synovialjoints/status/1801931105437634880/photo/1

Grappa « difficult to treat and complex to manage» PsA meeting - SLR, Patient & rheumo survey, working on definition eg - fail 1 csDMARD & 2 bDMARDs different MOA @RheumNow #EULAR2024

CAR-T - autologous vs allogenic , need for full induction , safety of retreatment, CAR-T lymphoma/leukaemia, cost, ideal candidate ? @RheumNow #EULAR2024

opposing point of view to previous post @RheumNow #EULAR2024 https://t.co/T72r8kXF1j

• https://twitter.com/drpnash/status/1801930003543687293/photo/1

#EULAR2024 POS1325 Childhood onset #lupus is often more severe with high mortality rate. Similar to findings in adults, 2 cSLE patients with refractory disease including failure to CyC, RTX & PLEX responded to CD19 CAR T cells with similar short term safety profile @RheumNow https://t.co/YD2arjxcso

• https://twitter.com/Yuz6Yusof/status/1801929946215993345/photo/1

lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @RheumNow #EULAR2024

Frank Buttgereit discusses potential reason for ceiling effect in RA and questions why we don’t use more combination therapy in RA (including low dose of of GC), using the example of Hypertension guidelines Is long term low dose GC in RA really a desirable option? @RheumNow… https://t.co/Nc7lldN7Nd https://t.co/63K96uuhKG

• https://twitter.com/i/web/status/1801927886011556002
• https://twitter.com/AurelieRheumo/status/1801927886011556002/photo/1
• https://twitter.com/AurelieRheumo/status/1801927886011556002/photo/1

Tips to help in self-management. Procrastination is a huge barrier to self-management. Delegate and prioritise #EULAR2024 Andrea Marques @RheumNow https://t.co/SbQgOMwqL0

• https://twitter.com/synovialjoints/status/1801927854638141535/photo/1
• https://twitter.com/synovialjoints/status/1801927854638141535/photo/1

Steroids are often started before pts see a rheumatologist This associates with long-term low-dose steroid use Need better collaboration between referrers and rheum to reduce this avoidable steroid burden POS0137 @RheumNow #EULAR2024

#EULAR2024 POS0436 Another benefit of T2T to achieve remission by using less NSAIDs, lower GC, earlier use of SFZ, HCQ and TNF-i = shorter Time to Pregnancy from conception in #RA women (median 84 days) vs without pre-counselling & T2T (196 days) @RheumNow https://t.co/2ZpDLmPVt0

• https://twitter.com/Yuz6Yusof/status/1801926586620313822/photo/1

Data form TARA trial Taper in RA remission Flare free survival at 2 yrs 35% Risk of flare is similar in ACPA+ & ACPA- RA Risk of flare is similar if taper TNFi first or csDMARD first @RheumNow #EULAR2024 POS0405 https://t.co/89gAglHUcw

• https://twitter.com/AurelieRheumo/status/1801925729971569102/photo/1

POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa Retrospective study in French THIN database Diagnostic delay remains common Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain @RheumNow #EULAR2024